liu.seSearch for publications in DiVA
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Impact of age on survival after intensive therapy for multiple myeloma: A population-based study by the Nordic Myeloma Study Group
Lund University Hospital, Lund, Sweden, Department of Haematology, University Hospital, SE-221 85 Lund, Sweden.
Department of Internal Medicine, Lidköping Hospital, Lidköping, Sweden.
Lund University Hospital, Lund, Sweden.
Rikshospitalet, Oslo, Norway.
Vise andre og tillknytning
2006 (engelsk)Inngår i: British Journal of Haematology, ISSN 0007-1048, E-ISSN 1365-2141, Vol. 133, nr 4, s. 389-396Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

The value of intensive therapy, including autologous stem cell transplantation, in newly diagnosed myeloma patients >60 years is not clear. We evaluated the impact of age (<60 years vs. 60-64 years) on survival in a prospective, population-based setting and compared survival with conventionally treated historic controls. The prospective population comprised 452 patients registered between 1998 and 2000. Of these, 414 received intensive therapy. The historic population, derived from our most recent population-based study on conventional therapy, comprised 281 patients. Of these, 243 fulfilled our eligibility criteria for intensive therapy. For patients undergoing intensive therapy it was found that two factors, beta-2-microglobulin and age <60 years vs. 60-64 years, had independent prognostic impact on survival. However, compared with the historic controls a survival advantage was found both for patients <60 (median 66 months vs. 43 months, P < 0.001) and 60-64 years (median 50 months vs. 27 months, P = 0.001). We conclude that in a population-based setting higher age adversely influences outcome after intensive therapy. Our results indicate that intensive therapy prolongs survival also at age 60-64 years but with less superiority than in younger patients. © 2006 Blackwell Publishing Ltd.

sted, utgiver, år, opplag, sider
2006. Vol. 133, nr 4, s. 389-396
Emneord [en]
Age, Myeloma, Population based, Survival, Transplantation
HSV kategori
Identifikatorer
URN: urn:nbn:se:liu:diva-50229DOI: 10.1111/j.1365-2141.2006.06042.xOAI: oai:DiVA.org:liu-50229DiVA, id: diva2:271125
Tilgjengelig fra: 2009-10-11 Laget: 2009-10-11 Sist oppdatert: 2017-12-12

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekst

Personposter BETA

Juliusson, Gunnar

Søk i DiVA

Av forfatter/redaktør
Juliusson, Gunnar
Av organisasjonen
I samme tidsskrift
British Journal of Haematology

Søk utenfor DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric

doi
urn-nbn
Totalt: 81 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf